References
- Pinals R S. Sulfasalazine in the rheumatic disease. Semin Arthritis Rheum 1988; 17: 246–59
- Farr M, Scott D GI, Bacon P A. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986, suppl. 1: 49–53
- Bax D E, Amos R S. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis 1986; 45: 13940
- Martin L, Sitar D S, Chalmers I M, Hunter T. Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity. J Rheumatol 1985; 12: 270–3
- Bax D E, Greaves M S, Amos R S. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 1986; 25: 282–4
- Amos R S, Pullar T, Bax D E, Situnayake D, Capell H A, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 744 patients monitored for one to 11 years. Br Med J 1986; 293: 420–3
- Arnett F C, Edworthy S M, Bloch D S, Mc Shane D J, Fries J F, Cooper N S, et al. The american Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
- Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference zones. Acta Radiol Diagn 1977; 18: 481–90
- Williams H J, Ward J R, Dahl S L, Clegg D O, Willkens R F, Oglesby T, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31: 702–13
- Pullar T, Hunter J A, Capell H A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. BrJ Rheumatol 1985; 24: 269–76
- Donovan S, Hawley S, Mac Carthy J, Scott D L. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study. Br J Rheumatol 1990; 29: 201–4
- Pinals R S, Kaplan S B, Lawson J G, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum 1986; 29: 1427–34
- Chalmers I M, Sitar D S, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990; 17: 764–70
- Stunayake R D, Grindulis K A, McConkey B. Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177–83
- Pullar T, Hunter J A, Capell H A. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 1985; 44: 831–7
- Farr M, Symmons D PM, Blake D R, Bacon P A. Neutropenia in patients with inflammatory arthritis treated with sulphasalazine. Ann Rheum Dis 1986; 45: 761–4
- Mitrane M P, Singh A, Seibold J R. Cholestasis and fatal agralulocytosis complicating sulfasalazine therapy: case report and review of the literature. J Rheumatol 1986; 13: 969–72
- Marabani M, Madhok R, Capell H A, Hunter J A. Leucopenia during sulphasalazine treatment for rheumatoid arthritis. Ann Rheum Dis 1989; 48: 505–7
- The Australian Multicenter Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992; 19: 1672–7
- Farr M, Symmons D PM, Bacon P A. Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid arthritis patients treated with sulphasalazine. Ann Rheum Dis 1985; 44: 798–800
- Bliddal H, Stangerup M. Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy. Clin Rheumatol 1991; 10: 178–80